Media Room

Media Room

 
Sep 05, 2012
Vancouver, B.C. September 5th, 2012 -- biOasis Technologies Inc. (TSX:V.BTI) announced today that a key animal study in its BT2111 oncology program, showed that BT2111, biOasis' conjugate of trastuzumab (Herceptin(r)) designed to treat brain metatastsis of HER2+ breast cancer, arrests the growth tumors in a xenograft model of human breast carcinoma. The human tumor xenograft model is accepted industry-wide as a gold standard for assessing the performance of new and emerging
 
 

You can view the Previous Media Room item: Thu Sep 6, 2012, Rokmaster Receives Final Approval of the Pinaya Property Option and Closes First Tranche of Non-Brokered Private Placement

You can view the Next Media Room item: Mon Jun 18, 2012, biOasis Enters Research & Evaluation Agreement with Abbott

You can return to the main Media Room page, or press the Back button on your browser.

Email 'biOasis's Herceptin<html>&reg;</html>-BT2111 Stops...' to a friendShow printable version of 'biOasis's Herceptin<html>&reg;</html>-BT2111 Stops...' in a New Window